| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,354,138 | 32 | 100 |
| Brady James Aloysius | director | 0 | $0 | 1 | $60,036 | $-60,036 |
| PERSKY MARLA | director | 0 | $0 | 1 | $91,433 | $-91,433 |
| HALKUFF DAWN | director | 0 | $0 | 1 | $121,886 | $-121,886 |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | director | 0 | $0 | 2 | $203,922 | $-203,922 |
| Shannon John Patrick Jr | See Remarks | 0 | $0 | 2 | $349,658 | $-349,658 |
| Pieper Steven | See Remarks | 0 | $0 | 5 | $515,213 | $-515,213 |
| JOHNSON JOHN | director | 0 | $0 | 2 | $1.07M | $-1.07M |
| Hecht Beth | See Remarks | 0 | $0 | 12 | $1.46M | $-1.46M |
| McCulloch Kevin | See Remarks | 0 | $0 | 6 | $1.48M | $-1.48M |
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in …
Over the last 12 months, insiders at Xeris Biopharma Holdings, Inc. have bought $0 and sold $5.35M worth of Xeris Biopharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Xeris Biopharma Holdings, Inc. have bought $302,183 and sold $2.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $109,475 was made by McCulloch Kevin (See Remarks) on 2025‑06‑13.
| 2026-10-01 | Sale | McCulloch Kevin | See Remarks | 15,000 0.0088% | $9.41 | $141,120 | +11.46% | |
| 2026-10-01 | Sale | Pieper Steven | See Remarks | 5,000 0.0029% | $9.41 | $47,037 | +11.46% | |
| 2026-10-01 | Sale | Hecht Beth | See Remarks | 16,666 0.0098% | $9.41 | $156,792 | +11.46% | |
| 2026-09-28 | Sale | McCulloch Kevin | See Remarks | 25,000 0.0147% | $10.00 | $250,000 | +3.81% | |
| 2026-09-01 | Sale | McCulloch Kevin | See Remarks | 15,000 0.0087% | $8.49 | $127,308 | +17.50% | |
| 2026-09-01 | Sale | Pieper Steven | See Remarks | 5,000 0.0029% | $8.50 | $42,500 | +17.50% | |
| 2026-09-01 | Sale | Hecht Beth | See Remarks | 16,666 0.0097% | $8.49 | $141,434 | +17.50% | |
| 2026-08-12 | Sale | Pieper Steven | See Remarks | 5,000 0.0029% | $8.50 | $42,500 | +4.83% | |
| 2026-08-03 | Sale | McCulloch Kevin | See Remarks | 15,000 0.0087% | $8.02 | $120,240 | +7.50% | |
| 2026-08-03 | Sale | Hecht Beth | See Remarks | 16,666 0.0096% | $8.01 | $133,553 | +7.50% | |
| 2026-07-07 | Sale | Pieper Steven | See Remarks | 27,600 0.0163% | $8.52 | $235,276 | -3.08% | |
| 2026-07-06 | Sale | Pieper Steven | See Remarks | 17,400 0.0102% | $8.50 | $147,900 | +3.58% | |
| 2026-07-01 | Sale | McCulloch Kevin | See Remarks | 90,000 0.0523% | $8.03 | $722,511 | +8.25% | |
| 2026-07-01 | Sale | Hecht Beth | See Remarks | 16,666 0.0097% | $8.03 | $133,860 | +8.25% | |
| 2026-06-04 | Sale | JOHNSON JOHN | director | 15,000 0.0086% | $6.09 | $91,422 | +38.54% | |
| 2026-06-04 | Sale | BORMANN-KENNEDY BARBARA-JEAN ANNE | director | 16,000 0.0092% | $6.09 | $97,507 | +38.54% | |
| 2026-06-04 | Sale | HALKUFF DAWN | director | 20,000 0.0115% | $6.09 | $121,886 | +38.54% | |
| 2026-06-03 | Sale | PERSKY MARLA | director | 15,500 0.009% | $5.90 | $91,433 | +44.40% | |
| 2026-06-01 | Sale | Hecht Beth | See Remarks | 16,667 0.0096% | $6.06 | $100,982 | +39.79% | |
| 2026-05-01 | Sale | Hecht Beth | See Remarks | 16,667 0.01% | $6.23 | $103,805 | +33.04% |
| Shannon John Patrick Jr | See Remarks | 2705346 1.4838% | $28M | 6 | 2 | +19.99% |
| McCulloch Kevin | See Remarks | 1599208 0.8771% | $16.55M | 1 | 6 | +58.85% |
| Pieper Steven | See Remarks | 1351053 0.741% | $13.98M | 2 | 5 | +20.95% |
| Hecht Beth | See Remarks | 1111130 0.6094% | $11.5M | 3 | 13 | +37.91% |
| PERSKY MARLA | director | 126500 0.0694% | $1.31M | 1 | 2 | +52.24% |
| HALKUFF DAWN | director | 95000 0.0521% | $983,250.00 | 1 | 2 | +32.42% |
| Redmile Group, LLC | 10 percent owner | 3000642 1.6458% | $31.06M | 2 | 0 | <0.0001% |
| Edick Paul R | See Remarks | 2288064 1.255% | $23.68M | 10 | 0 | +1.38% |
| Palmetto Partners, Ltd. | 10 percent owner | 2110061 1.1573% | $21.84M | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 856470 0.4698% | $8.86M | 1 | 10 | <0.0001% |
| SHERMAN JEFFREY W | director | 219188 0.1202% | $2.27M | 1 | 1 | +32.07% |
| Deutsch Barry M. | See Remarks | 39359 0.0216% | $407,365.65 | 2 | 0 | +5.12% |
| Schmid John P. | director | 25200 0.0138% | $260,820.00 | 5 | 0 | +56.98% |
| JOHNSON KENNETH ERLAND | See Remarks | 6115 0.0034% | $63,290.25 | 2 | 0 | +5.12% |
$607,395,062 | 99 | 4.23% | $1.88B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
Xeris Biopharma Holdings, Inc. (XERS) | $61,893,001 | 38 | 19.63% | $1.89B |
| Increased Positions | 117 | +42.86% | 16M | +16.28% |
| Decreased Positions | 119 | -43.59% | 13M | -13.7% |
| New Positions | 37 | New | 3M | New |
| Sold Out Positions | 42 | Sold Out | 4M | Sold Out |
| Total Postitions | 271 | -0.73% | 101M | +2.58% |
| Blackrock, Inc. | $87,669.00 | 7.19% | 11.93M | +391,378 | +3.39% | 2025-09-30 |
| Vanguard Group Inc | $72,235.00 | 5.92% | 9.83M | +10,980 | +0.11% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $42,923.00 | 3.52% | 5.84M | +2M | +52.26% | 2025-09-30 |
| Geode Capital Management, Llc | $30,430.00 | 2.49% | 4.14M | +489,486 | +13.41% | 2025-09-30 |
| State Street Corp | $27,477.00 | 2.25% | 3.74M | -44,871 | -1.19% | 2025-09-30 |
| Qube Research & Technologies Ltd | $24,070.00 | 1.97% | 3.27M | +185,063 | +5.99% | 2025-09-30 |
| Morgan Stanley | $23,665.00 | 1.94% | 3.22M | -422,883 | -11.61% | 2025-09-30 |
| Nuveen, Llc | $20,785.00 | 1.7% | 2.83M | +227,432 | +8.75% | 2025-09-30 |
| Driehaus Capital Management Llc | $19,251.00 | 1.58% | 2.62M | +548,054 | +26.46% | 2025-09-30 |
| Rosalind Advisors, Inc. | $13,199.00 | 1.08% | 1.8M | -359,828 | -16.69% | 2025-09-30 |